Sun Pharma Q2: ₹1,269 Crore Exceptional Loss Hits PAT; CFO Explains Organon Impact | Business News
ET Now · 02 Nov 2026 · 6 min
Management interview of Sun Pharmaceutical Industries Ltd (SUNPHARMA), with 1 key numbers discussed.
- Jayshree Satagopan, CFO, Sun Pharma
Sun Pharma CFO Jayshree Satagopan stated that the Organon acquisition is expected to conclude in early Q4 FY27, targeting nearly $350mn in synergies over a 2-3 year period across the value chain. Gross margins improved marginally even after adjusting for the Lenalidomide base effect. Addressing the softness in Ilumya sales, the company has expanded its sales force and secured regulatory approval for a new psoriatic arthritis indication. In the domestic formulations market, volume growth and generic Semaglutide traction continue to drive momentum, while annual guidance remains held.